— Bio-Path Holdings Inc. (NASDAQ: BPTH) reported a loss of $3.24 share for the full year 2019, narrower than a loss of $14.38 per share in the previous year.
— Research and development expenses remained flat from the last year at $4.6 million.
— General and administrative expenses were $4.1 million during the year ended December 31, 2019, up 21% from last year, primarily due to increased legal fees and salaries and benefits expense.
— The company is in the process of initiating a phase 1 study of second pipeline candidates in the first half of this year to evaluate the ability of BP1002 to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia patients.
— The company is nearing completion of an investigational new drug (IND)-enabling studies of BP1003 for the treatment of solid tumors, including pancreatic cancer, and expects to file an IND application for phase 1 study in 2020.
— Following the successful completion of the safety testing in Stage 2 of phase 2 clinical trial of prexigebersen in acute myeloid leukemia (AML), the company now plans to advance this program to its next stage in the first half of 2020.
— The company filed an IND application for prexigebersen in the treatment of solid tumors including ovarian and endometrial cancer and expects to start that study later this year.
Most Popular
What to look for when CVS Health (CVS) reports Q3 earnings
Healthcare company CVS Health Corporation (NYSE: CVS) is all set to report earnings next week, with Wall Street expecting a mixed outcome. The company has been facing challenges in certain
eBay (EBAY): A few factors that helped drive growth in Q3 2024
Shares of eBay Inc. (NASDAQ: EBAY) stayed green on Friday. The stock has gained 32% year-to-date. The ecommerce leader delivered revenue and earnings growth for the third quarter of 2024,
CVX Earnings: Chevron reports lower revenue and profit for Q3 2024
Energy exploration company Chevron Corporation (NYSE: CVX) on Friday announced third-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation dropped to